# The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

> **NCT06620809** · PHASE1 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 69 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders

## Interventions

- **DRUG:** Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection
- **DRUG:** A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection

## Key facts

- **NCT ID:** NCT06620809
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-28
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06620809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06620809, "The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06620809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*